Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084409 · ClinicalTrials.gov registry record · Phase 2
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
A Phase 2 study of Lung Cancer and Precancerous Condition, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 6
- Study locations
NCT00084409: Completed Phase 2 study of Lung Cancer and Precancerous Condition, sponsored by University of Colorado, Denver.
NCT00084409 is a Phase 2 study of Lung Cancer and Precancerous Condition that has completed, run by University of Colorado, Denver. The registered enrollment target is 152 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084409, a Phase 2 study of Lung Cancer and Precancerous Condition, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease.
Primary Outcome
This outcome measure is created for each subject as follows: From all biopsies scored at the baseline bronchoscopy, the mean WHO score is calculated. From all biopsies scored at the follow-up bronchoscopy, the mean WHO score is calculated.Histology on bronchial biopsies pre-treatment and post-treatment will be compared. All biopsies will be graded according to the WHO classification for bronchial epithelium for this outcome, and all the following outcomes. WHO Classification Grade Normal 1.0
Conditions Studied
Interventions
- OTHER placebo
- DRUG iloprost
Study Locations (6)
Colorado
- University of Colorado Cancer Center at UC Health Sciences Center - Aurora
- Veterans Affairs Medical Center - Denver - Denver
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Minnesota
- Mayo Clinic Cancer Center - Rochester
Pennsylvania
- UPMC Cancer Centers - Pittsburgh
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00084409 record still lists
NCT00084409 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00084409 lists 6 locations in 5 states (Colorado, Maryland, Minnesota).
Frequently Asked Questions
What is clinical trial NCT00084409 about?
NCT00084409 is a clinical study titled "Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at...
What is the current status of trial NCT00084409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2001-11. Estimated completion is 2009-01.
What conditions does trial NCT00084409 study?
This clinical trial studies the following conditions: Lung Cancer, Precancerous Condition.
What interventions are being tested in trial NCT00084409?
The interventions under investigation include: placebo (OTHER), iloprost (DRUG).
Who is sponsoring clinical trial NCT00084409?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00084409 being conducted?
This trial has 6 study locations across Colorado, Maryland, Minnesota, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00084409's enrollment target sits among peer trials
152 147th of 409 higher than 263 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia